Acne vulgaris is not a hygiene problem. It is an inflammatory skin condition driven by four interconnected pathways: hyperactive sebaceous glands producing excess oil, abnormal keratinisation blocking pore openings, proliferation of Cutibacterium acnes bacteria within the clogged follicle, and a cascade of inflammatory cytokines that produce the redness and swelling we see on the surface. Treating only one pathway — as most over-the-counter washes do — explains why breakouts so frequently return.
AC.NET is a biotechnological active complex developed for topical application. At a concentration of 3 percent, clinical trials demonstrate three measurable outcomes within 42 days: a 44 percent decrease in total sebum production, 100 percent inactivation of C. acnes in vitro, and significant normalisation of keratinocyte turnover. Unlike benzoyl peroxide, AC.NET achieves antibacterial action without generating free radicals or causing the dryness and peeling that many users experience.
Genevia's Aloederm Face Lotion pairs AC.NET at the full 3 percent clinical dose with two complementary actives. Aloe Vera barbadensis provides anti-inflammatory soothing, reducing erythema around existing lesions. Tea Tree Oil (Melaleuca alternifolia) contributes additional antibacterial activity through its terpinen-4-ol content, which disrupts bacterial cell membranes via a mechanism distinct from AC.NET — reducing the likelihood of resistance development.
The formulation is designed as a lightweight lotion rather than a thick cream, making it suitable for oily and combination skin types that are most prone to acne. It is non-comedogenic (will not block pores), fragrance-adjusted for sensitive skin, and dermatologically tested on volunteers with active acne lesions. The recommended protocol is twice-daily application after cleansing, with visible improvement typically observed from week three.
What makes the AC.NET approach particularly relevant in 2024 is the global push to reduce antibiotic use in dermatology. The World Health Organisation has listed antimicrobial resistance as one of the top ten global public health threats. Topical antibiotics like clindamycin and erythromycin, once first-line acne treatments, are now associated with rising resistance rates. Non-antibiotic alternatives like AC.NET offer comparable efficacy without contributing to this problem.
For patients with moderate acne who have not responded to salicylic acid or benzoyl peroxide alone, or who find retinoids too irritating, AC.NET-based formulations present a clinically supported middle ground. Aloederm can be used alongside prescription treatments or as a standalone regimen for mild to moderate cases.